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Abstract: Androstenedione is a steroidal hormone produced in male and female gonads, as well as
in the adrenal glands, and it is known for its key role in the production of estrogen and testosterone.
Androstenedione is also sold as an oral supplement, that is being utilized to increase testosterone
levels. Simply known as “andro” by athletes, it is commonly touted as a natural alternative to anabolic
steroids. By boosting testosterone levels, it is thought to be an enhancer for athletic performance, build
body muscles, reduce fats, increase energy, maintain healthy RBCs, and increase sexual performance.
Nevertheless, several of these effects are not yet scientifically proven. Though commonly used as
a supplement for body building, it is listed among performance-enhancing drugs (PEDs) which
is banned by the World Anti-Doping Agency, as well as the International Olympic Committee.
This review focuses on the action mechanism behind androstenedione’s health effects, and further
side effects including clinical features, populations at risk, pharmacokinetics, metabolism, and
toxicokinetics. A review of androstenedione regulation in drug doping is also presented.
Keywords: androstenedione; health effects; toxicity; pharmacokinetics; metabolism; drug
interaction; pharmacogenetics
1. Introduction and Occurrence
Steroidal hormones are the key players in the stress response and reproduction in
mammals. Consequently, they have been considered health biomarkers in both land and
aquatic wildlife [1]. Androstenedione or 4-Androstene-3-17-dione (4A) is a naturally occur-
ring steroidal hormone produced in both sexes from the gonads and adrenal glands [2] and
serving as an intermediate in the biosynthesis of testosterone [3]. It is produced mainly at
normal conditions by the adrenals (2–3 mg/day) and testis (0.5 mg/day). Bone is the target
organ of androgens, which affect both the maturation of bones as well as the homeostasis
of mature bones. Androgen deficiency is linked to premature bone loss [4] and with the
elevated frequency of osteoporotic features in men [5]. The treatment of postmenopausal
women with anabolic steroids favorably impacts the bone mass [6]. Androgens stimulate
human and murine osteoblast-like cells proliferation in vitro [7]. Androgen receptors are
also characterized in cultured human osteoblast-like cells [8], suggesting that they can act
directly on bone cells via a receptor-mediated mechanism [9].
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Currently, androstenedione is frequently administered to bodybuilders and ath-
letes [10], due to its effect as an immediate precursor to testosterone in the androgens’
intrinsic synthetic pathways [11]. Androstenedione is sold without medical prescription
in the United States and the sport supplementation market registered annual revenue of
1.4 billion in 1999 [? ], with expectation to continue growing [12]. The administration of
androstenedione as a supplement has become more popular among athletes, especially
after the MLB player Mark McGuire admitted using it during his historic 1998 chase of
Roger Maris’s single-season home run record [13]. Consequently, androstenedione is sold
to athletes as a potential anabolic agent [12], and the sport supplement industry is profiting
some multimillion dollars per year.
Nutraceuticals are used as dietary supplements to be used for the treatment or pre-
vention of several diseases [14]. Androstenedione is not typically considered among
nutraceuticals or regulated by the Food and Drug Administration (FDA) owing to the
ongoing debate about its therapeutic effectiveness for preventing or treating certain chronic
diseases such as anxiety and improving mental acuity [15]. Nowadays, licensed healthcare
professionals and physicians often prescribe dietary supplements of androstenedione to
counteract the effects of age-related muscle loss (sarcopenia) to improve lifespan as well as
quality of life in older people [16]. However, the use of androstenedione in some individ-
uals, including athletes, can cause an increase in the testosterone to epitestosterone ratio
(T/E) above the International Olympic Committee (IOC) cut-off of 6 [17,18], which is likely
to occur in men who take testosterone [19]. The reason behind the increase in the T/E ratio
is an increase in urinary excretion of testosterone concurrent with a decrease in urinary
excretion of epitestosterone [12].
Several androgens are secreted by the endocrine glands, including androstenedione,
5-androstene-3b,17b-diol (androstenediol), dehydroepiandrosterone sulfate (DHEAS), and
dehydroepiandrosterone (DHEA) [20]; see Figure 1. The androgenic hormones, dehy-
droepiandrosterone (DHEA) and androstenedione, are produced by the adrenal glands
and act as precursors in the estrogen and testosterone hormones production [21,22]. Their
production peaks during the mid-20s and then starts to decline in a controlled manner after
the third decade of life [23].
Figure 1. Diagram showing the secretion origins of the main androgenic hormones (steroids) from
both adrenal glands and gonads.
2. Methods
To conduct this review, an electronic search was performed via the PubMed, SciFinder,
Scopus, Google Scholar, Web of Science, and Science Direct search engines. The keywords
used were “Androstenedione; health effects; toxicity; pharmacokinetics; metabolism; drug
interaction; pharmacogenetics”. Both review articles and original studies focusing on the
topic of the review were included from 1976 to 2020. We excluded papers for which only
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an abstract was found, preprints, and conference proceedings. Androstenedione toxicity
was reported only from the oral administration not from the indigenous hormone.
3. Distribution in Nature
Steroidal hormones in nature, as illustrated in Figure 2, can be found in human and
animal sources, septic systems, concentrated animal feeding operations, combined sewer
overflows, wastewater treatment plants, and agricultural fields [24–26]. Once steroid
hormones are present in surface water, they are subjected to several biotransformation
and removal processes, such as sorption to sediments or colloids, direct or indirect photo-
degradation, and biodegradation [27–29].
Figure 2. Steroid hormones’ various origins in nature, including human and animal sources, septic
systems, concentrated animal feeding operations, combined sewer overflows, wastewater treatment
plants, and agricultural fields.
Androstenedione was also found in the Fenholloway River water column, likely
derived from the microbial degradation of several phytosteroids, such as stigmastanol,
β-sitosterol, and campesterol. For instance, the microbial conversion of phytosterols is
being widely applied for the production of steroidal drug intermediates such as AD and
9-OHAD (9-hydroxy-4-androstene-3,17-dione) [30–32]. These phytosteroids are found in
wastes created from the conversion of pine tree into pulp [33].
In aquatic habitats, where there is huge effluent release from livestock farms, national
sewage treatment plants, and pulp and paper factories [34], elevated levels of androstene-
dione were detected in Beijing in the sewage from seven different wastewater treatment
plants at levels ranging from 5 ng/L to 270 ng/L [35]. It was also detected in Guangdong
Province in two other different types of wastewater treatment plants at mean levels of
(1368 ± 283) ng/L [36], and in natural waterways at levels up to 480 ng/L in Japan [37].
These residues of androstenedione could cause substantial risks to aquatic organisms as
well as humans upon further exposure. Previous studies have described the adverse effect
of androstenediones on the aquatic systems. For instance, laboratory and field studies
discovered the masculinization of Gambusia holbrooki, the female mosquitofish, living in
water and contaminated by pulp mills [38], specifically with androstenedione and an-
drostadienedione (ADD) [34,39]. Furthermore, Hou [40] explored the endocrine disruption
induced by androstenedione over the growth cycle of zebrafish embryos. The authors
reported that the levels of mRNA of some primary genes (Lhb, Hsd20b, Star, Cyp19a,
Fshb, Vtg1, Pomc), which participate in the receptor signaling pathways, were altered
after exposure to androstenedione, suggesting that androstenedione’s adverse effects are
observed throughout the growth of zebrafish embryos [40]. Whether such changes in gene
Molecules 2021, 26, 6210 4 of 16
levels could be also observed in humans following ingestion of these contaminated fish
have yet to be reported.
The purpose of this review is to provide insights into and critical analysis of an-
drostenedione as a natural hormone, along with its different metabolic reactions. Extensive
knowledge regarding androstenedione consumption, action mechanisms for its health
benefits and side effects, in addition to its pharmaco/toxicokinetics and clinical features is
presented for the first time.
4. Androstenedione Distribution and Metabolism
4.1. Absorption and Distribution
The study of androstenedione and its derivatives’ interaction with plasma proteins
is of value to provide insight into the bioavailability and distribution of these specific
molecules [41], with various biological actions. Plasma proteins typically bind reversibly to
the hydrophobic hormones, drugs, and metabolites and are circulating in the bloodstream
to extend their clearance time from the body. The importance of the binding affinity of
plasma proteins lies in the fact that it can help to determine free and effective concentrations
of drugs, and further regulate their pharmacodynamic and pharmacokinetic properties [42].
Lipoproteins, α1-acid glycoprotein (AGP) and human serum albumin (HSA) are the ma-
jor carriers of proteins in blood plasma [42]. As mentioned earlier, the natural steroid
hormone, 4-androstene-3-17-dione (4A), is produced in the adrenal glands and gonads.
Physiologically, 4A, in the existence of 3-oxo-5-β-steroid-4- dehydrogenase, is converted
into the 5β-androstane-3-17-dione (5A) steroid molecule. On the other hand, (+)-6-methyl-
5β-androstane-3-17-dione (6M) is another steroidal hormone derivative where a methyl
group is connected to the C6 position of 5β-androstane-3-17-dione [41], as illustrated in
Figure 3. Moreover, 4A is also an immediate precursor for testosterone via the action of
17-β-hydroxysteroid dehydrogenase [43]; see Figure 4A,B.
Figure 3. The chemical equation of the enzyme-catalyzed reaction of 4-androstene-3-17-dione (4A) hormone with 3-
oxo-5-β-steroid-4- dehydrogenase enzyme to produce 5β-Androstane-3-17-dione (5A), followed by the production of
(+)-6-methyl-5β-androstane-3-17-dione (6M) with a methyl group attached at the C6 position [41].
Nerusu [41] and his colleagues reported that 6M, 4A, and 5A steroid molecules
can form stable complexes with AGP and HSA, with higher binding affinity to HSA
than AGP [41]. The binding constants obtained for 6M, 4A, and 5A with HAS were
(9.5 ± 0.2) × 104, (5.3 ± 2) × 104, and (5.3 ± 1) × 104 M−1, respectively, compared to
(2.1 ± 0.7) × (104, 7.4 ± 4) × 103, and (2.6 ± 0.6) × 103 M−1 with AGP for 6M, 4A, and 5A,
respectively [41]. Consequently, HAS-androstenedione and its derivative complexes were
stabilized after 15 ns and found to maintain their stable structures [41].
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Figure 4. Production of steroidal hormones from cholesterol, including androstenedione production by the enzyme 3ß-HSD2
in both adrenal glands (A) and testis (B), as well as the production other essential androgens throughout the enzymatic
reaction. Androstenedione is highlighted in pink in both cycles. Enzyme codes are: Steroidogenic Acute Regulatory
protein (StAR), Cytochromes P450, Sulfotransferase (SULTs), 3-β hydroxysteroid dehydrogenase (3β-HSD), and aromatase
cytochrome P450 (P450aro).
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4.2. Metabolism
Sometimes termed androstenedione, 4-Androstene-3-17-dione (4A) is considered the
key intermediate in steroid metabolism [41]. The metabolism of androstenedione in the
different biological systems is presented in the next subsections.
4.2.1. Metabolism in Fungi
One of the most well-studied biotransformation of testosterone, androstenedione, and
progesterone derivatives was carried out in a cultured fungi strain of Absidia coerulea [44].
All of the examined substrates were transformed or hydroxylated, which enabled re-
searchers to isolate biotransformed metabolites [44]. The same author and his colleagues
studied the transformation of testosterone, androstenedione, and progesterone derivatives
with an extra C1-C2 double bond and/or 17 α-methyl group in a cultured fungi strain of
Absidia coerulea as a model to assess the eukaryotic biotransformation of steroids, includ-
ing 4A. Although the substrates included the 4-ene-3-oxo system, they displayed some
differences in the substituents at C-17 and/or the existence of the additional C1-C2 double
bond.
4.2.2. Metabolism in Humans and Non-Human Primates
Firstly, 11-oxygenetad steroids circulate in the body with different serum levels,
varying among species, with the highest levels detected in humans and non-human
primates [45]. The major chemicals in the synthesis of steroid drugs are known as 4-
androstene-3,17-dione (androstenedione, AD) and 1,4-androstadiene-3,17-dione (androsta-
dienedione, ADD). One of the crucial physiological mechanisms in mammalian organisms
is steroid hydroxylation because of its role in pro-drug activation or the detoxification of
exogenous steroids [46]. The formation of androgenic products is based on the availabil-
ity of the needed substrates [47]. For instance, androstanedione was reported to be the
principal metabolite of androstenedione in human fetal epiphyseal cartilage [48] and in
human hair roots [49]. Androstenedione can be synthesized from dehydroepiandrosterone
and further converted into either testosterone through the action of 17β- hydroxysteroid
dehydrogenase, or to estrone via the aromatase enzyme complex [50]. DHEA is converted
into androstenedione in the adrenal cortex, where it can be either aromatized to estrone
or de-hydrogenated in the liver to yield testosterone [51]. Gene polymorphisms that en-
code for key enzymes involved in such pathways could have a modulation effect on the
endogenous hormone levels; hence, it can influence the risk of hormone-related cancer
diseases [52,53], and it can account for different responses to steroids in humans.
It is worth mentioning that the metabolism of androgens, in vivo, in bone could be
more challenging than under in vitro conditions due to the hormone regulation of enzyme
activities [9]. Androgens are circulated through the peripheral tissues in the body, which is
followed by immense metabolism and subsequent excretion in urine [54]. Metabolism of
androgen takes place mainly via hydroxysteroid dehydrogenases, reductases, and conju-
gation enzymes [54]. Additionally, progesterone is biosynthesized from pregnenolone as
an intermediate product of androstenedione and testosterone biosynthesis in the testicles,
as well as in the adrenal cortex to a certain extent [55]. On the other hand, testosterone is
converted in an extensive manner into androstenedione, and only a very small percentage
of the testosterone that is assembled in the body is metabolized to testosterone glucuronide
and detected in urine [54]. Moreover, DHEA and androstenedione are metabolized primar-
ily to androsterone etiocholanolone and androsterone [54]. Androstenedione in the blood
can turn into testosterone and further to estradiol or 5α-dihydrotestosterone (DHT) in
peripheral tissues. In other cases, androstenedione can be converted into estrone and then
estradiol without testosterone formation [55]; see Figure 4B. Moreover, androstenedione
can be metabolized and converted into several potent estrogens or androgens, such as
estradiol, estrone, or testosterone [56], as illustrated in Figure 4A.
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4.2.3. Metabolism in Animals and Rodents
The main identified metabolites of androstenedione in cattle are oestradiol-17 and epitestos-
terone [57]—see Figure 5—whereas the main metabolite in sheep is the 17-epimer [58]. Fur-
thermore, 3(17)-hydroxysteroid dehydrogenase (HSD) enzyme, which has been detected
in kidney and liver tissues from hamsters and rabbits, is a possible candidate involved
in the conversion of androstenedione to epitestosterone [59]. Moreover, 17-HSD enzyme
has been isolated and characterized from an intestinal Eubacterium sp. [60], suggesting that
colon bacteria could also play a role in androstenedione metabolism. The effect of the
gut microbiota on the metabolism of androstenedione and its different analogues is less
well-understood, especially given the inter-individual variability of gut composition, and
should be examined in the future.
Figure 5. The main identified metabolites of androstenedione in cattle and the freshwater ramshorn
snail Marisa cornuarietis in both males and females.
Valdés [61] studied the oxidative metabolism of androstenedione in rats during star-
vation and in a streptozotocin (STZ) animal model of diabetes in order to detect any
similarities or differences that could be observed under these two conditions. Results
revealed that the ketotic conditions in both cases of diabetes and fasting animals were
accompanied by higher levels of free fatty acids or their metabolites [61]. This was asso-
ciated with distinct alterations in the metabolic activities, which is specific to individual
cytochrome P450 associated with androstenedione metabolism; see Figure 4 [61].
Androstenedione has been identified in various invertebrate (animals without back-
bones) species and tissues [62]. Vertebrates and other invertebrates are known for their
ability to metabolize androstenedione to testosterone (T) via a 17β-hydroxysteroid dehydro-
genase (17β-HSD)-catalyzed pathway [63]. In invertebrates, microsomal fractions obtained
from the digestive gland/gonad complex of Marisa cornuarietis, the freshwater ramshorn
snail, revealed that androstenedione is largely converted to 5α-dihydrotestosterone (DHT)
and testosterone (T) in males versus to 5α-dihydroandrostenedione (DHA) in females, as
shown in Figure 5 [64]. Furthermore, the ratio of 17-reduced metabolites (DHT and T)
versus DHA was higher in males (3–42) than that detected in females (0.13–0.78) in all cases
and regardless of the sampling time [65]. More importantly, the conversion of testosterone
into epitestosterone by androstenedione is highly unlikely to occur as many attempts to
illustrate this pathway have failed [46]. However, other potential pathways could exist and
have yet to be confirmed [12].
Molecules 2021, 26, 6210 8 of 16
5. Hormonal Effects of Androstenedione AD (or 4A)
Androstenedione (androst-4-ene-3,17-dione) is an intermediate endogenous androgen
that leads to the biosynthesis of testosterone, in addition to its exogenous administration
in dietary supplements [66]. In this section, we review effects reported for endogenous
androstenedione as well as exogenously administered in dietary supplements in both sexes.
5.1. Hormonal Effects of AD in Males
The effect of androstenedione supplementation on exercising and basal testosterone
levels has been extensively reported from supplementation at dosages of 100–200 mg
of androstenedione in humans [10,67]. A study conducted by Wallace [68] reported a
basal testosterone level of 6.1 ng/mL for the participants with a mean age of (48.1 ± 3.9)
years after the administration of androstenedione (100 mg) for a 12 weeks. To support
these findings, another study reported by Leder [10] revealed that 100 mg supplementa-
tion of androstenedione per day for 7 days was not sufficient to raise testosterone levels
in men, whereas a significant increase in testosterone levels was observed at a 300 mg
dose level to reach in participants testosterone levels of 4.93 ng/mL, with a mean age of
31.5 years [10]. Such a result was in accordance with a previous report in which an oral
300 mg dose of androstenedione for 7 days showed an increase in testosterone levels,
suggesting that short-term supplementation of androstenedione at 300 mg can significantly
increase testosterone responses in older men [69].
5.2. Hormonal Effects of AD in Females
A study was conducted at the same dosage of 100 mg androstenedione (single dose,
oral) in healthy postmenopausal women by Leder [70] in which they explored the ef-
fects of androstenedione on the serum levels sex steroids. After the administration of
androstenedione (100 mg), serum levels of estrone were increased by up to 115% over 12 h
in comparison to the control, versus a 450% increase in testosterone level over 12 h at the
same dosage relative to the control [70]. Whether such a large increase in testosterone
levels in women could lead to androgenic effects has yet to be examined. Similar results
were observed by Kicman [71] from a single dose androstenedione (100 mg) on plasma
testosterone over 24 h in 10 healthy young ladies at ca.16-fold greater than the control
group. Such observed testosterone levels were comparable to those noticed in the misuse of
testosterone for anabolic purposes, suggesting deleterious side effects of the modified sex
hormone levels in women receiving androstenedione [71]. Other reports have supported
these earlier observations in young women after the administration of androstenedione
(100–300 mg, single dose) leading to increase in both serum estradiol (1.5–2 times) and
serum testosterone by (5–10 times) at 4 h after dose administration [72], confirming a much
greater increase in the male sex hormone than female sex hormones with androstenedione
administration. In other words, the ingestion of androstenedione (100 or 200 mg) does not
alter serum testosterone concentrations in young men [10,67], while ingesting of a single
dose of 100–300 mg androstenedione leads to a 34% increase in the levels of serum total
testosterone that lasts for 4–6 h [10].
5.3. Hormonal Effects of AD in Children
Children with obesity suffer from higher levels of adrenal androgen than their normal
counterparts, which could lead to accelerated pre-pubertal growth in these children [73].
Kwon [74] and his colleagues examined the association between bone age (BA) and chrono-
logical age (CA) ratio (BA/CA) and androstenedione and testosterone levels. The effects
of androgens or their metabolites on the skeleton are employed by direct stimulation of
the estrogen receptor (ER) α, ER β and androgen receptor (AR). The expression of the
androgen receptor (AR) was measured at several ages with no major sex difference in the
human growth plate chondrocytes. As a result, androgens such as androstenedione may
have an essential role in bone maturation in pre-pubertal children of both sexes [75].
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5.4. Hormonal Effects in Female Rats
Hormone replacement therapy is a potential strategy for the protection of bones
from postmenopausal osteoporosis [76]. However, there are multiple disadvantages due
to their potential harmful side effects in other organs [77]. It is unclear whether an-
drostenedione could impact the levels of physiological hormones by changing the liver
enzyme activities that metabolize steroid hormones or not. Hence, Flynn [78] conducted
a study on mature female rats, where they were gavaged with androstenedione (0, 5,
30, or 60 mg/kg/day) two weeks before mating and continued through gestation day
19. In addition, non-pregnant female rats were gavaged for the same timeframe with
androstenedione (0 or 60 mg/kg/day) and the liver was further dissected from preg-
nant rats on gestation day 20, as well as from non-pregnant rats after five weeks of treat-
ment [78]. Liver microsomes were incubated with testosterone, leading to the production of
6-hydroxytestosterone, 15-hydroxytestosterone, 7- hydroxytestosterone, 16- hydroxytestos-
terone, and 2-hydroxytestosterone at high levels compared to controls. The formation of
6-hydroxytestosterone was observed at both 30 and 60 mg/kg/day dose levels. On the
other hand, in non-pregnant rats, androstenedione (60 mg/kg/day) markedly increased
the formation of 15-, 6-, 16 -, and 2 -hydroxytestosterone [78]. The results highlighted that
high oral doses of androstenedione could enhance some female rat liver cytochrome P450
activities that metabolize steroid hormones [78,79]. It is worth noting that there were no
response differences among androstenedione doses between pregnant and non-pregnant
female rats [78].
6. Receptors of Androstenedione
Steroid receptors nowadays are receiving increasing attention, considered to be respon-
sible for many regulatory complexities within the vertebrate lineage [80,81]. Moreover, the
nuclear receptor superfamily is an ancient lineage of transcription factors that are activated
by small ligands [82]. It is also hypothesized that nuclear steroid receptors emerged at
or before the radiation of vertebrates. However, the androgen receptor (Ar) evolved only
in the gnathostome line [83]. The androgen-Ar complex was found in the extant jawless
vertebrate male sea lamprey (Petromyzon marinus) [83]. The detected androgen with the
highest affinity was androstenedione (Ad).
A study was conducted by Zucker [84] to explore the effects of androstenedione on
thromboxane A2 (TXA2) receptor expression in rat aortic smooth muscle (RASM) cells
and Human Erythroleukemia (HEL) cells [84]. The latter have been used as a model
of megakaryocytes, which is the progenitor cell for platelets [85]. Both cell lines were
incubated with androstenedione (250, 500, or 750 nM), testosterone (150 nM), or the vehicle
for a period of 48 h. The results revealed that androstenedione is capable of increasing the
number of TXA2 receptors in HEL cells, as well as in RASM cells, significantly, with no
significant change in affinity [84].
7. Androstenedione Doping
Androstenedione encompasses potential health risks as a typical steroid, especially
if it is abused [86]. Consequently, the US Food and Drug Administration mandated that
androstenedione-contained products should not be marketed or distributed as other dietary
supplements [87].
The use of over 100 doping agents is prohibited by the Medical Commission of the
International Olympic Committee (IOC) for athletes and these agents are classified into
five categories including anabolic agents [88]. Several athletes, however, use different types
of anabolic–androgenic steroids (AAS), from synthetic anabolic steroids (i.e., stanozolol) to
natural hormones (i.e., testosterone), administered by injection in order to increase their
muscular mass and to upgrade their performance in training sessions [89]. The misuse
of these restricted anabolic steroids is controlled by assessing the existence of the banned
substances or any of their biotransformed metabolites in urine samples from athletes [90].
An androstenedione German patent reported that the ingestion of androstenedione by
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young individuals can lead to an increase in serum levels of testosterone by ca. 237% within
15 min, and this is followed by a secondary increase of 48–97% within 3 to 4 d [91]. Such
increased levels in serum testosterone appear to represent solid responses to this dietary
supplementation, while it has been reported on the World Anti-Doping banned list [92].
To assess the metabolism of anabolic steroids in humans, Lévesque [93] and his
colleagues studied androstenedione and norandrostenedione to evaluate their in vitro incu-
bations. These two steroids are precursors of testosterone and nortestosterone, respectively,
and they are banned by the Medical Commission of the IOC as well [88].
8. Androstenedione Toxicity
The weak androgen, androstenedione, was found to be converted to stronger
carcinogenic estrogens or androgens, including estradiol estrone or testosterone [94].
A limited number of studies have investigated the carcinogenic or tumor-promoting
activities of androstenedione. As early as 1957, Bischoff [95] and his team reported that
androstenedione increased the number of fibrosarcomas over 18 months, tested as a by-
product, in male Marsh-Buffalo mice when subcutaneously injected for one to two times per
2-month period in a dose of 15 mg/mouse. Another study by Dauvois [96] reported
that androstenedione administration increased the tumor size in ovariectomized rats
when the level of androstenedione was kept at 500 µg (similar to those found in the
circulation of post-menopausal women) and this was more attributed to the conversion
of androstenedione to estradiol. Co-administration of an aromatase inhibitor blocked the
former effect. Additionally, dehydroepiandrosterone (DHEA, androstenedione precursor)
enhanced hepatocellular carcinomas, induced by hepatocarcinogen aflatoxin B1, in rats
and rainbow trout at a daily dosage of 222 ppm, which corresponds to half of that of the
dose administered to humans in clinical trials [97,98].
In contrast, the administration of androstenedione at three dose levels, namely 5,
30, or 60 mg/kg body weight/day, in pregnant rats initiated 2 weeks before mating and
continued till day 19 of gestation revealed no significant differences in biomarkers of
hepatotoxicity, including aspartate aminotransferase, serum alanine aminotransferase,
glutathione, and glutathione S-transferase, lipid peroxidation, lactate dehydrogenase, total
microsomal P450, and nuclear DNA damage on gestation day 20 [99]. Another study by
Wieczerzak [100] demonstrated that androstenedione showed no effect on serum total
triglycerides, cholesterol, or HDL-cholesterol, suggesting that it does not affect the lipid
profile, but it significantly decreased prostaglandin E2 in pregnant and non-pregnant rats
and C-reactive protein in pregnant rats. To sum up, oral androstenedione appears not
to cause overt hepatotoxicity in pregnant female rats, although it demonstrated modest
changes in lipid metabolism that may facilitate the persistence of damaged cells due to a
declined tissue repair rate, which in turn favors disease progression [100]. In other words,
androstenedione does not cause liver damage; however, it causes modest changes in lipid
metabolism that worsen the present liver damage in the human body.
A side effect of androstenedione administration at 100 mg in 10 healthy females
produced supraphysiological concentrations of plasma testosterone in healthy women,
suggesting that the misuse of anabolic steroids, especially for women, may lead to the devel-
opment of male characteristics such as male pattern baldness, clitomegaly, voice deepening,
hirsutism, abnormal menstrual cycles and abnormal bleeding, blood clots, and metabolic
disruption; see Figure 6B. The latter would be very harmful for women, especially those
of childbearing age, asides from an increased risk for breast and endometrial cancer [101].
Consequently, drug regulatory authorities should consider classifying androstenedione
under the same category as testosterone to control its dispensing and administration.
Another study revealed similar results in rats when administering androstenedione (1.0,
5.0, 10.0, or 30.0 mg/kg body weight) for two weeks before mating [102]. They reported
that androstenedione at such dose levels significantly increased serum androstenedione,
estradiol, and estrone at gestation day 20 in all treated groups. Meanwhile, the serum
testosterone concentration was significantly elevated in the 30 mg/kg dose group only,
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with no observed side effects [102]. The number of female animals showing regular estrous
cycles was significantly reduced in the 10.0 and 30.0 mg/kg dose groups. The numbers of
implants, viable fetuses, and viable male fetuses were slightly decreased (not statistically
significant) in the 30.0 mg/kg androstenedione group. Whether such a hormonal increase
can also be observed in fetuses should be monitored for conclusive effects. Finally, an-
drostenedione exposure appears to affect implantation adversely; however, further studies
should be conducted with larger numbers of animals or ideally in humans.
Figure 6. Toxic effects of androstenedione drug supplementation in (A) males, (B) females, and (C) children.
Sprando [101] and his colleagues repeated the same experiments but utilizing a larger
number of animals and at a higher dose of androstenedione, albeit with slight differences
in sampling times. Interestingly, and in contrast to their previous work, serum hormone
levels were not significantly affected by androstenedione administration compared to the
control group, which could likely be attributed to the rapid metabolism, as the serum
hormonal levels were immediately elevated after androstenedione administration and
returned subsequently to control values within 24 h [101]. Furthermore, within the two-
week pre-mating exposure period, the number of estrous cycles was decreased slightly
with the number of animals having irregular estrous cycles to show a slight increase in the
androstenedione group (60.0 mg/kg), in contrast to their previous study [102].
Owing to the ambiguous results regarding androstenedione’s effects in female animals,
the National Toxicology Program comprehensively investigated the sub- and chronic
toxicity and carcinogenicity in both male and female rats and mice at a broad range of
androstenedione dose levels (1, 5, 10, 20, 50 mg/kg/day) for 14 weeks in order to gain
more conclusive results [94]. Results revealed that androstenedione did not reveal any
dose-limiting toxicity in either female or male mice and rats. Although no genetic toxicity
was observed in the 14-week study, except for an equal response in the peripheral blood
micronucleus test that was observed with androstenedione (50 mg/kg/day) in female mice,
it was suggested that there is a potential adverse effect on male fertility and reproductive
performance. Such a hypothesis was based on reduced sperm counts in a dose-dependent
manner in the rat cauda epididymis by 17%, 20%, and 30% at 10, 20, and 50 mg/kg.
Compared to the acute study, the chronic study showed that androstenedione exhibited
carcinogenic effects in female and male mice livers, but it may or may not be carcinogenic
in rats [94]. Such results should be pursued further, especially given that androstenedione
is typically administered over a long-time span as a supplement for athletes.
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The side effects of androstenedione related to the increase in testosterone levels in
males are still not conclusive, with several reports of elevated serum testosterone and/or
estradiol levels [10,67], versus others showing no changes [67]. A consensus was reached
that, in most studies, androstenedione was unlikely to provide any anabolic benefit and may
even result in adverse health consequences, including sperm count reduction, impotence,
and gynecomastia and prostate enlargement, as shown in Figure 6A. Administration to
children and adolescents could lead to hormonal effects similar to those obtained upon the
cessation of bone growth in adults, early puberty, and pre-matures [101]; see Figure 6C.
The controversy of the toxicity results regarding androstenedione may be explained
by several factors: (1) time of serum selection—androstenedione has a high metabolic rate
and may be converted into estrogens directly, (2) sex differences, and (3) effects of the
surrounding environment, such as residual drug mixtures and pH. For instance, ketoprofen
in combination with androstenedione and estrone proved to be synergistically toxic. In
addition, the change in pH has a significant effect on the toxicity of androstenedione,
suggesting that androstenedione should not be combined with drugs that affect the pH of
the body, such as aspirin, or avoided in the case of lung or kidney disorders [100].
9. Conclusions
Androgens or steroids should be regulated with extensive medical supervision, specif-
ically androstenedione or 4-Androstene-3-17-dione (4A) and its derivatives. Their metabo-
lites affect humans and non-humans, i.e., fungi, animals, rodents. Moreover, athletes only
consider the increase in testosterone levels and bone maturation, disregarding the other
known and unknown consequences of the administration of such supplements. Addition-
ally, several of these positive effects are not yet fully scientifically proven. It was reported
that androstenedione is carcinogenic in male and female mice, with a limited number of
available androstenedione carcinogenic data, warranting more studies to provide a broader
view of the dosage limit to reduce, or prevent, such toxic effects. Obviously, many toxic
effects occur due to the supplementation of androstenedione among males, females, and
children in comparison to its benefits. This review aimed to provide detailed insights into
androstenedione’s consumption, metabolism, health effects, and toxicity. It is expected
that with more research data available regarding androstenedione drug supplementation,
greater control of the useful dose for human health will become possible.
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